Ross Acquisition Corp. II (ROSS) to Combine with APRINOIA Therapeutics in $319M Deal
Ross Acquisition Corp. II (NYSE:ROSS) has entered into a definitive agreement to combine with drug developer APRINOIA at an enterprise value of $319.6 million. Cambridge, Massachusetts-based APRINOIA is developing treatments and diagnostic tools for Alzheimer’s and Parkinson’s that target the toxic proteins that accelerate the diseases’ progression. The combined company may trade on the eitherRead More
To access this post, you must purchase 1 - User: Monthly Plan.